| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA345: Naloxegol for treating opioid‑induced constipation. |
|
Medicine details |
|
| Medicine name | naloxegol (Moventig®) |
| Formulation | 12.5 mg, 25 mg film-coated tablet |
| Reference number | 1218 |
| Indication | Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s) |
| Company | ProStrakan Ltd |
| BNF chapter | Gastro-intestinal system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/12/2014 |
| NICE guidance | |